Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C225-ILs-dox in relapsed/refractory glioblastoma
NCT03603379Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Antibody Fragments, Targeted Liposomes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-EGFR immunoliposomes loaded with doxorubicin in glioblastoma (GBM), sponsored by University Hospital Basel. Primary endpoint: Ratio of C225-ILs-dox concentration at 24 hours. Started Nov 2018; status: completed.
02
Drugs
anti-EGFR immunoliposomes loaded with doxorubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03603379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603379.